bms-387032 and Prostatic-Neoplasms

bms-387032 has been researched along with Prostatic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for bms-387032 and Prostatic-Neoplasms

Article	Year
Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer. Journal of medicinal chemistry, 2022, 08-25, Volume: 65, Issue:16 Aberrant hyperactivation of cyclins results in carcinogenesis and therapy resistance in cancers. Direct degradation of the specific cyclin or cyclin-dependent kinase (CDK)-cyclin complex by small-molecule degraders remains a great challenge. Here, we applied the first application of hydrophobic tagging to induce degradation of CDK9-cyclin T1 heterodimer, which is required to keep productive transcription of oncogenes in cancers. Topics: Cell Nucleus; Cyclin T; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinases; Cyclins; Humans; Male; Prostatic Neoplasms	2022

Article

Year

Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.

Journal of medicinal chemistry, 2022, 08-25, Volume: 65, Issue:16

Aberrant hyperactivation of cyclins results in carcinogenesis and therapy resistance in cancers. Direct degradation of the specific cyclin or cyclin-dependent kinase (CDK)-cyclin complex by small-molecule degraders remains a great challenge. Here, we applied the first application of hydrophobic tagging to induce degradation of CDK9-cyclin T1 heterodimer, which is required to keep productive transcription of oncogenes in cancers.

Topics: Cell Nucleus; Cyclin T; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinases; Cyclins; Humans; Male; Prostatic Neoplasms

2022